{"filing":{"accession_number":"0001651625-26-000016","cik":"0001651625","ticker":"ACIU","company_name":"AC Immune SA","form":"6-K","filing_date":"2026-08-11","report_date":"2026-08-11","primary_document":"aciu-20260811x6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1651625/000165162526000016/aciu-20260811x6k.htm"},"events":[{"id":26824,"run_id":24398,"accession_number":"0001651625-26-000016","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"AC Immune announced FDA Fast Track designation and IND clearance for ACI-7104, an anti-alpha-synuclein active immunotherapy for early Parkinson's disease. This is a material regulatory milestone enabling expansion of the Phase 2 VacSYn trial to U.S. sites, supported by positive interim safety and immunogenicity data. While not a discrete M\u0026A, financing, or executive event, this regulatory achievement materially advances the company's clinical development program and would affect a reasonable investor's assessment of pipeline progress and regulatory pathway.","company_name":"AC Immune SA","ticker":"ACIU","filing_date":"2026-08-11","form":"6-K","submitted_at":null,"items":[{"id":28093,"accession_number":"0001651625-26-000016","item_number":"EX-99.1","item_title":"aciu-20260811xex99d1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"AC Immune announced FDA Fast Track designation and IND clearance for ACI-7104, an anti-alpha-synuclein active immunotherapy for early Parkinson's disease. This is a material regulatory milestone enabling expansion of the Phase 2 VacSYn trial to U.S. sites, supported by positive interim safety and immunogenicity data. While not a discrete M\u0026A, financing, or executive event, this regulatory achievement materially advances the company's clinical development program and would affect a reasonable investor's assessment of pipeline progress and regulatory pathway.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-11T11:00:41.970391+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28093,"accession_number":"0001651625-26-000016","item_number":"EX-99.1","item_title":"aciu-20260811xex99d1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"AC Immune announced FDA Fast Track designation and IND clearance for ACI-7104, an anti-alpha-synuclein active immunotherapy for early Parkinson's disease. This is a material regulatory milestone enabling expansion of the Phase 2 VacSYn trial to U.S. sites, supported by positive interim safety and immunogenicity data. While not a discrete M\u0026A, financing, or executive event, this regulatory achievement materially advances the company's clinical development program and would affect a reasonable investor's assessment of pipeline progress and regulatory pathway.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-11T11:00:41.970391+00:00","company_name":"AC Immune SA","ticker":"ACIU","filing_date":"2026-08-11"}]}